Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) has issued an update.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has renewed its Sharing Agreement with Sunshine Lake Pharma for 2025, allowing the company to receive a percentage of sales revenue from designated pharmaceutical products in both centralized and non-centralized tender businesses. This agreement extends till the end of 2025 and stipulates that Sunshine Lake Pharma will provide a breakdown of revenues and profits, distributing them to YiChang HEC ChangJiang Pharmaceutical after annual audits. The renewal is based on multiple factors, including profit margins and cost-to-revenue ratios, and aims to continue the benefits derived from the sharing arrangement.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the distribution of pharmaceutical products in the People’s Republic of China. The company engages in connected transactions, collaborating with Sunshine Lake Pharma to distribute revenues and profits from designated pharmaceutical products.
YTD Price Performance: -2.41%
Average Trading Volume: 2,958,160
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$8.21B
Find detailed analytics on 1558 stock on TipRanks’ Stock Analysis page.
